TIMOGEN – The solution for the / m – Spray nazalynыy dozirovannыy

Active material: timogen
When ATH: L03AX
CCF: Immunostimulatory drug
ICD-10 codes (testimony): A56.0, A56.1, A56.4, J00, J01, J02, J03, J04, J06.9, J10, J15, J16.0, J20, J31, J32, J35.0, J37, J42, Z29.8
When CSF: 14.01.06
Manufacturer: MBNPK TSITOMED Company (Russia)

Pharmaceutical form, composition and packaging

The solution for the / m colorless, clear.

1 ml – ampoule (5) – packs cardboard.

◊ Spray nazalynыy dozirovannыy colorless, clear; allowed to have a characteristic smell BAK.

Excipients: benzalkonium chloride, sodium chloride, Sodium hydroxide 1M (to pH 6.5-7.5), Purified water.

3 ml – bottles with a dosing device (1) – packs cardboard.
5 ml – bottles with a dosing device (1) – packs cardboard.
10 ml – bottles with a dosing device (1) – packs cardboard.

Pharmacological action

Immunomodulatory drugs. It is a dipeptide, affect the reaction cell, humoral immunity and nonspecific resistance of the organism. It stimulates the regeneration processes in the event of their oppression, improve processes for cell metabolism. Strengthens the processes of differentiation of lymphoid cells, It has the ability to stimulate the colony-forming activity of bone marrow cells, induces the expression of receptors on lymphocytes differentiation, normalizes the number of T-helper cells, T-suppressors and their correlation in patients with various immunodeficiency.

Dipeptide activated CD4 expression⁺-receptors on lymphocytes in vitro. It was observed dipeptide with high affinity membrane receptors thymocytes, as well as the specific binding to the surface of lymphocytes timogena, that helps explain its immunomodulatory properties.

In experimental studies revealed radioprotective properties timogena^®, marked anti-inflammatory activity, as well as its ability to inhibit the development of serotonin and histamine edema, stimulate the formation of the corresponding antibodies. In in vitro studies found a modulating effect timogena^® cytokine production.

Pharmacokinetics

Pharmacokinetics preparation Timogen^® He has not been studied in connection with its peptide.

Testimony

- Complex therapy of acute and chronic infectious and inflammatory diseases, accompanied by a decrease in cellular immunity;

- Prevention of immunosuppression, hematopoiesis, regeneration processes in post-traumatic and post-operative period, in the course of radiotherapy or chemotherapy, using massive doses of antibiotics;

- Prevention and complex therapy of virus (incl. ARI and influenza), bacterial and chlamydial infections;

- Prevention and complex therapy of acute and chronic respiratory diseases.

Dosage regimen

The solution for the / m used / m and intranasally. Recommended doses for a / m and intranasal administration are:

Duration of therapy 3-10 days, depending on the severity of violations of immunity.

FROM prophylactically drug administered intranasally or / m daily adult by 100 g, children - By 50-75 xg for 3-5 days.

Spray nazalynыy dozirovannыy appointed adult by 1 dose (25 g) in each nostril 2 times / day; children aged 7 to 14 years – by 1 dose (25 g) in each nostril 1 time / day; children aged 1 Year to 6 years – by 1 dose (25 g) in one nostril 1 time / day. The drug is prescribed for 10 days with the purpose of treatment and during 3-5 days – prophylactically.

When administered to a spray nozzle of the vial with a metering device is inserted into the nostril at a position vertically upwards and pressed once.

If necessary, may conduct repeated course through 1-6 Months.

Side effect

Maybe: allergic reactions.

Contraindications

- Pregnancy;

- Lactation (breast-feeding);

- Hypersensitivity to the drug.

Pregnancy and lactation

Contraindicated during pregnancy and lactation (breast-feeding).

Cautions

There is evidence of the effectiveness of timogena^® as an immunomodulator, reducing immune reactivity, in the complex therapy of viral hepatitis, TB, psevdotuberkuleza, influenza and acute respiratory viral infections, papillomatoza, Sepsis.

According to clinical studies the use of timogena^® during the acute phase of the disease in the form of intestinal amebiasis, typhoid fever, acute dysentery, Roger, Diphtheria, brucelleze, hemorrhagic fever with renal syndrome improves the health of patients, It contributes to a more rapid normalization of biochemical and immunological parameters. As a result, the drug reduced the incidence of prolonged relapsing course of disease and chronic process.

Application timogena^® at bronchopulmonary diseases, infectious and inflammatory and allergic etiology can reduce duration of illness, restore the activity of the immune system and prevent or substantially reduce the likelihood of complications.

According to clinical studies Timogen^® successfully used in the complex therapy of bacterial, viral and fungal infections of the skin (pyoderma, abrasions, faces, papillomatoza, Herpes), and in the treatment of atopic dermatitis.

In the medical literature published allegations of timogena^® in the complex therapy of acute pancreatitis, peritonitis, in severe mechanical injuries, crush syndrome, burns, the treatment and rehabilitation of patients after major abdominal operations.

Not recommended simultaneous application timogena^® with corticosteroids at high doses.

Overdose

Symptoms: at a 10-fold overdose may develop a flu-like syndrome.

Drug Interactions

In a joint application Timogen^® increases the effectiveness of cytostatic and radiotherapy.

Conditions of supply of pharmacies

Solution for i / m administration by prescription.

Metered nasal spray is approved for use as a means of non-prescription.

Conditions and terms

List B. Solution for i / m administration should be stored in a dark place at a temperature not exceeding 4 ° C. Shelf life – 3 year.

Nasal spray dosage should be stored in a dry, protected from light, inaccessible to children at temperature from 0 ° to 25 ° C. Shelf life - 2.5 year.